The calcium sensitizer levosimendan was associated with an improvement in the clinical course of patients compared with placebo when used for the treatment of acute decompensated heart failure (ADHF), but the drug failed to reduce 6-month mortality when compared with dobutamine in a similar set of patients.
The calcium sensitizer levosimendan was associated with an improvement in the clinical course of patients compared with placebo when used for the treatment of acute decompensated heart failure (ADHF), but the drug failed to reduce 6-month mortality when compared with dobutamine in a similar set of patients.
The REVIVE II (Randomized Multicenter Evaluation of Intravenous Levosimendan Efficacy) trial evaluated levosimendan administered over 24 hours (12 mcg/kg bolus followed by 0.2 mcg/kg/min) plus standard therapy or standard therapy alone in 600 patients with ADHF. The primary end point was a composite of clinical signs and symptoms together with the occurrence of death or worsening heart failure over 5 days.
After 5 days, the likelihood of clinical improvement was 33% greater and the likelihood of clinical deterioration was 29% lower in patients randomized to levosimendan versus placebo (P=.015), reported Milton Packer, MD, professor and director of the Center for Biostatistics, University of Texas Southwestern Medical Center, Dallas, Texas. Also, fewer patients randomized to levosimendan compared with placebo required rescue therapy (15.1% vs 26.2%), and the average hospital stay was shorter among the levosimendan group (7.0 vs 8.9 days; P=.001).
In the SURVIVE (Survival of Patients with Acute Heart Failure in Need of Intravenous Inotropic Support) trial, 1,327 patients with ADHF were randomized to either the same dosing schedule of levosimendan as used in REVIVE II or dobutamine (minimum dosage, 5 mcg/kg/min).
The primary end point was all-cause mortality at 180 days. Although there was a clear trend toward improved survival with levosimendan, the 9.0% reduction in mortality at 180 days in the levosimendan-treated patients failed to achieve statistical significance (26% vs 28%; P=.401), said Alexandre MeBazaa, MD, PhD, principal investigator of SURVIVE, and professor and director, Department of Anesthesia and Critical Care Medicine, Lariboisiere Hospital, Paris, France.
In both studies, levosimendan-treated patients had a higher incidence of atrial fibrillation and hypotension versus the comparator and a lower incidence of cardiac failure.
Get the latest industry news, event updates, and more from Managed healthcare Executive.
PBM-Offered Genomics Testing Could Reshape Prescribing of Medications
July 25th 2025Two PBMs, True Rx Health Strategies and Capital Rx, are using pharmacogenomics — how a person’s DNA affects their response to medications — to reduce the trial-and-error of prescribing medications, saving employers and patients time and money.
Read More
David Calabrese of OptumRx Talks Top Three Drugs in Pipeline, Industry Trends in Q2
July 1st 2020In this week's episode of Tuning Into The C-Suite podcast, MHE's Briana Contreras chatted with David Calabrese, R.Ph, MHP, who is senior vice president and chief pharmacy officer of pharmacy care services company, OptumRx. David is also a member of Managed Healthcare Executives’ Editorial Advisory Board. During the discussion, he shared the OptumRx Quarter 2 Drug Pipeline Insights Report of 2020. Some of the information shared includes the three notable drugs currently being reviewed or those that have been recently approved by the FDA. Also discussed were any interesting industry trends to watch for.
Listen
FDA Extends Review of Blenrep Combinations in Multiple Myeloma
July 24th 2025Last week, an FDA advisory committee against the risk-benefit profile of Blenrep in combination with other therapies. Regulators and reviewers were concerned about the ocular side effects and dosing and tolerability. The new action date is Oct. 23, 2025.
Read More
Sarepta to Pause Shipments of the Gene Therapy Elevidys
July 22nd 2025Sarepta officials said the temporary halt in shipments was done to maintain a productive working relationship with regulators while they address a safety labeling update about the risk of acute liver disease related to Elevidys.
Read More